Atossa Genetics

Yahoo Finance • 18 days ago

Atossa Therapeutics GAAP EPS of -$4.04 misses by $0.22

* Atossa Therapeutics press release [https://seekingalpha.com/pr/20451740-atossa-therapeutics-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-a] (ATOS [https://seekingalpha.com/symbol/ATOS]): FY GAAP EPS of -$4.04... Full story

Yahoo Finance • 25 days ago

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financi... Full story

Yahoo Finance • 8 months ago

Advanced Authentication Market Outlook Report 2025-2029: Advanced Authentication Market to Surge by USD 75.57 Billion from 2024-2029, Driven by Online Transactions Boom

Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Advanced Authentication Market 2025-2029" has been added to ResearchAndMarkets.com's offering. The advanced authentication market is projected to expand by USD 75.57 billion from 2024 to 2... Full story

Yahoo Finance • 8 months ago

Atos posts H1 drop in orders and revenue on weak demand, tough market backdrop

Investing.com -- French IT company Atos reported a drop in both revenue and orders for the first half (H1) of the year, citing weak commercial activity in France and a difficult market backdrop. Order intake reached €3.3 billion over the... Full story

Yahoo Finance • 9 months ago

Atos shares climb 4% after reporting stronger half-year liquidity position

Investing.com -- Atos (EPA:ATOS) shares rose 4% on Monday after the company published its estimated half-year liquidity figures, showing a sharp reduction in cash outflows compared with the previous year. For the first half of 2025, the F... Full story

Yahoo Finance • 9 months ago

France stocks higher at close of trade; CAC 40 up 1.44%

Investing.com – France stocks were higher after the close on Wednesday, as gains in the Healthcare, Financials and Industrials sectors led shares higher. At the close in Paris, the CAC 40 rose 1.44% to hit a new 1-month high, while the SB... Full story

Yahoo Finance • 10 months ago

BofA assesses the impact of foreign tax in budget bill on European software names

Investing.com - European software companies stand to be hit by a section of a massive Republican budget bill which would tax foreign investors in the United States. The proposed tax, included in Section 899 of the package, would slap a pr... Full story

Yahoo Finance • 12 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

SEATTLE, April 22, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Unit... Full story

Yahoo Finance • last year

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

SEATTLE, March 20, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the Comp... Full story

Yahoo Finance • last year

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced its... Full story

Yahoo Finance • last year

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591

SEATTLE, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the foll... Full story

Yahoo Finance • last year

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that... Full story

Yahoo Finance • 2 years ago

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story

Yahoo Finance • 2 years ago

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Achieved significant enrollment milestones in ongoing Phase 2 clinical trials Four ongoing Phase 2 studies evaluating (Z)-endoxifen, including recently announced study in DCIS Ended third quarter 2023 with $94.0 million of cash and cash eq... Full story

Yahoo Finance • 2 years ago

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story

Yahoo Finance • 3 years ago

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on b... Full story

Yahoo Finance • 3 years ago

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

SEATTLE, July 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story

Yahoo Finance • 3 years ago

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

SEATTLE, July 10, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast... Full story

Yahoo Finance • 3 years ago

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on br... Full story

Yahoo Finance • 3 years ago

Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial

New York --News Direct-- Atossa Therapeutics Inc Atossa Therapeutics CEO Steven Quay joined Proactive's Natalie Stoberman to discuss the latest progress in its Phase 2 I-SPY 2 clinical trial where six patients have been dosed with Atossa’... Full story